Excess mortality with erythropoietins

The MHRA has asked manufacturers of recombinant human erythropoietins (r-HeEPOs) to update their safety advice, following publication of data showing a consistent, unexplained excess mortality in patients with anaemia associated with cancer.

In addition, studies suggest that treatment of anaemia with r-HeEPOs in patients with chronic kidney disease to achieve relatively high target haemoglobin levels may be associated with an increased risk of mortality and cardiovascular morbidity.

The new advice outlines changes to dose recommendations, including, where necessary, to stipulate a uniform target haemoglobin concentration range of 10—12 g/dL. Haemoglobin levels higher than 12g/dL should be avoided

Further information: MHRA

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases